Sugi Predict

Sugi Predict / Compounds / SCHEMBL559965

SCHEMBL559965

SCHEMBL559965

CC(C)(C)[Si](C)(C)Oc1cccc(CO)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.41
▸ CA12 O43570 4/20 0.41
▸ CA1 P00915 4/20 0.41
▸ CA9 Q16790 4/20 0.41
▸ GPBAR1 Q8TDU6 1/20 0.40
▸ CYSLTR1 Q9Y271 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ PDK1 Q15118 1/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ PDK3 Q15120 1/20 0.38
▸ PDK4 Q16654 1/20 0.38
▸ NR1H4 Q96RI1 1/20 0.38
▸ IDO1 P14902 2/20 0.38
▸ AGXT P21549 2/20 0.38
▸ PRKCI P41743 1/20 0.38
▸ F10 P00742 1/20 0.37
▸ NR1H2 P55055 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29851528 1.00 KDR (0.41) KDRCA12CA1CA9GPBAR1
SCHEMBL2635979 0.87 CYP4F2 (0.50) CA12CA1CA9HSP90AA1HSP90AB1
SCHEMBL378877 0.85 CA12 (0.42) CA12CA1CA9TSHRHSP90AA1
SCHEMBL29975825 0.85 CA12 (0.42) CA12CA1CA9TSHRHSP90AA1
SCHEMBL14382682 0.85 CA12 (0.42) CA12CA1CA9TSHRSMN1; SMN2
SCHEMBL4327915 0.83 CA12 (0.44) CA12CA1CA9HSP90AA1HSP90AB1
SCHEMBL3866939 0.83 MAOB (0.43) CA12CA1CA9IDO1AGXT
SCHEMBL558917 0.83 CA12 (0.41) CA12CA1CA9TSHRSMN1; SMN2
SCHEMBL15125782 0.83 PRKCI (0.50) KDRNR1H4PRKCI
SCHEMBL3235704 0.83 CYP1A2 (0.49) CA12CA1CA9HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2024-11-21 — — US disclosed
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use JANSSEN PHARMACEUTICA NV (BE) 2024-08-20 — — US disclosed
US-20230097422-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2023-03-30 — — US disclosed
CN-113121562-B Polycyclic compounds as inhibitors of bruton's tyrosine kinase 詹森药业有限公司 2022-09-13 — — CN disclosed
CN-113105475-B Inhibitors of bruton's tyrosine kinase and methods of use thereof 詹森药业有限公司 2022-09-09 — — CN disclosed
US-11319329-B2 Inhibitors of Bruton's tyrosine kinase and methods of their use JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 — — US disclosed
CN-113121562-A Polycyclic compounds as inhibitors of bruton's tyrosine kinase 詹森药业有限公司 2021-07-16 — — CN disclosed
CN-113105475-A Inhibitors of bruton's tyrosine kinase and methods of use thereof 詹森药业有限公司 2021-07-13 — — CN disclosed
US-20210101910-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2021-04-08 — — US disclosed
US-10934310-B2 Inhibitors of Bruton's tyrosine kinase and method of their use JANSSEN PHARMACEUTICA NV (BE) 2021-03-02 — — US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 — — US disclosed
EP-1453822-A4 DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES GIRI BRIJ P (US) 2004-11-24 — — EP disclosed
EP-1453822-A2 DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES Giri, Brij P. (US) 2004-09-08 — — EP disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 — — EP disclosed
WO-2003054506-A2 DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES GIRI BRIJ PAL (US) 2003-07-03 — — WO disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 — — US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 — — WO disclosed
US-6348478-B1 BLOOD COAGULATION FACTORS AND ANTICOAGULANTS TEIJIN LIMITED (JP) 2002-02-19 — — US disclosed
EP-1043311-A1 BIPHENYLAMIDINE DERIVATIVES TEIJIN LIMITED (JP) 2000-10-11 — — EP disclosed
US-5854249-A Opioid diarylmethylpiperazines and piperidines DELTA PHARMACEUTICALS, INC. (US) 1998-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934310-B2 Inhibitors of Bruton's tyrosine kinase and method of their use ABL1, BTK, LYN KDR 1251/4885CA12 4457/4885CA1 4319/4885
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use ABL1, BTK, LYN KDR 1251/4885CA12 4457/4885CA1 4319/4885
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE ABL1, BTK, MYLK2 KDR 1310/4885CA12 4464/4885CA1 4239/4885
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 KDR 1806/4885CA12 3611/4885CA1 2801/4885
US-20230097422-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE ABL1, BTK, LYN KDR 1251/4885CA12 4457/4885CA1 4319/4885
US-20210101910-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE ABL1, BTK, MYLK2 KDR 1310/4885CA12 4464/4885CA1 4239/4885
US-11319329-B2 Inhibitors of Bruton's tyrosine kinase and methods of their use ABL1, BTK, MYLK2 KDR 1310/4885CA12 4464/4885CA1 4239/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 KDR 1806/4885CA12 3611/4885CA1 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.